These forward-looking statements include statements relating to the potential of EOS-215 to be best in class and the potential benefits of EOS-215 and iTeos’ novel PTPN1/2 inhibitor. These ...

These forward-looking statements include statements relating to the potential of EOS-215 to be best in class and the potential benefits of EOS-215 and iTeos' novel PTPN1/2 inhibitor. These forward ...

iTeos has developed a novel small molecule inhibiting PTPN1/2. The PTPN1/2 phosphatases are negative regulators of cytokine signaling pathways and T cell receptor signaling. Inhibiting or ...

iTeos has developed a novel small molecule inhibiting PTPN1/2. The PTPN1/2 phosphatases are negative regulators of cytokine signaling pathways and T cell receptor signaling. Inhibiting or depleting ...

Nerio Therapeutics Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a tyrosine-protein phosphatase non-receptor type 1 ...

Chang said the drug targets PTPN1, a protein tyrosine phosphatase that plays a role in the regenerative capacity of muscle stem cells. By using this drug, they can tamper the activity of that protein.

Nerio’s small molecules inhibit the protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2), which act as immune checkpoints. Through this mechanism, PTPN1/2 inhibition can activate the immune ...

Nerio’s small molecules inhibit the protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2), which act as immune checkpoints. Through this mechanism, PTPN1/2 inhibition can activate the immune ...